Fishunter , I concur with everything you say. Not sure where the price will be in 6 months time ($10?, $20?, $30?) , what I am sure of is that, if Emricasan is approved first for NASH Cirrhosis and then extended for other Liver Cirrhosis seigoloite(if ph2b results confirm ph2a results we might see an accellerated approval without ph3), the stock will be trading in the thousands $$ within a few years.
I see a gradual appreciation as we approach the main 2017 catalyst which is the start of the LF ph2b trial, which will most likely trigger Novartis option exercise. Then a big jump up, and then a gradual appreciation until 2018 ph2b's read outs , then another big jump up.
So between now and LF trial start announcement in 2017 we may still have a chance to accumulate at extremely low prices (probably between $5 and $10) and i will not miss this chance
News 
Market Data 
Discover 
AI
